ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

Hawking Hearings Turn Up Difference Between Management, Staff At FDA

November 20, 1981

Consolidation Unlikely to Save Money

December 17, 2010

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

October 7, 1977

In Brief: No More Shifts Planned For Treatment Programs; Groups Seek Surgeon, Radiologist Incentives

August 29, 1975

DCT Board Restores Funding to Rosenberg’s Lymphocyte Projects

June 17, 1994

In Brief: Waxman Now Key House Health Figure; Kennedy Subcommittee Beefed Up with Top Democrats

February 9, 1979